PortfoliosLab logo
Alvotech Warrant (ALVOW)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date

Jun 16, 2022

Highlights

Total Revenue (TTM)

$452.85M

Gross Profit (TTM)

$287.49M

EBITDA (TTM)

$1.64M

Year Range

$1.02 - $4.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alvotech Warrant, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%200.00%250.00%300.00%December2025FebruaryMarchAprilMay
45.00%
54.47%
ALVOW (Alvotech Warrant)
Benchmark (^GSPC)

Returns By Period

Alvotech Warrant (ALVOW) returned -53.38% year-to-date (YTD) and -55.38% over the past 12 months.


ALVOW

YTD

-53.38%

1M

35.51%

6M

-51.99%

1Y

-55.38%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of ALVOW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-28.30%1.35%-33.19%-12.58%9.85%-53.38%
202463.20%22.06%-33.73%-1.82%-2.16%-5.68%-6.35%-10.71%4.80%16.03%-10.53%14.34%24.40%
202362.90%61.06%-2.87%-36.71%-34.67%26.53%29.03%18.12%2.12%-22.28%26.00%32.28%168.82%
2022-16.00%-12.11%1.58%-7.00%2.57%-21.72%66.07%-7.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALVOW is 22, meaning it’s performing worse than 78% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ALVOW is 2222
Overall Rank
The Sharpe Ratio Rank of ALVOW is 2929
Sharpe Ratio Rank
The Sortino Ratio Rank of ALVOW is 3636
Sortino Ratio Rank
The Omega Ratio Rank of ALVOW is 3636
Omega Ratio Rank
The Calmar Ratio Rank of ALVOW is 55
Calmar Ratio Rank
The Martin Ratio Rank of ALVOW is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alvotech Warrant (ALVOW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Alvotech Warrant Sharpe ratio is -0.41. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Alvotech Warrant with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-0.41
0.48
ALVOW (Alvotech Warrant)
Benchmark (^GSPC)

Dividends

Dividend History


Alvotech Warrant doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-75.00%
-7.82%
ALVOW (Alvotech Warrant)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alvotech Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alvotech Warrant was 81.72%, occurring on May 1, 2025. The portfolio has not yet recovered.

The current Alvotech Warrant drawdown is 75.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-81.72%Feb 27, 2024254May 1, 2025
-68.42%Mar 8, 202372Jun 29, 202398Jan 5, 2024170
-59.69%Oct 25, 202214Nov 16, 202225Dec 23, 202239
-37.62%Jun 27, 202215Jul 18, 202250Oct 24, 202265
-27.34%Dec 29, 20222Dec 30, 20224Jan 9, 20236

Volatility

Volatility Chart

The current Alvotech Warrant volatility is 74.18%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%December2025FebruaryMarchAprilMay
74.18%
11.21%
ALVOW (Alvotech Warrant)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alvotech Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Alvotech Warrant is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALVOW relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALVOW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALVOW in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALVOW has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items